carvedilol has been researched along with Alloxan Diabetes in 9 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was to assess effects of carvedilol on ventricular remodeling and expression of β3-adrenergic receptor (β3-AR) and Gi protein in a rat model of diabetes subjected to myocardial infarction (MI)." | 7.83 | Effects of carvedilol on ventricular remodeling and the expression of β3-adrenergic receptor in a diabetic rat model subjected myocardial infarction. ( Fu, L; Kang, X; Shen, J; Wang, F; Wang, Y; Yu, P; Zhang, R, 2016) |
| "This study was to assess effects of carvedilol on ventricular remodeling and expression of β3-adrenergic receptor (β3-AR) and Gi protein in a rat model of diabetes subjected to myocardial infarction (MI)." | 3.83 | Effects of carvedilol on ventricular remodeling and the expression of β3-adrenergic receptor in a diabetic rat model subjected myocardial infarction. ( Fu, L; Kang, X; Shen, J; Wang, F; Wang, Y; Yu, P; Zhang, R, 2016) |
| "Carvedilol treatment increased activities of antioxidant enzymes and expression of Bcl-2 in healthy rats as well as diabetic rats." | 1.34 | Carvedilol improved diabetic rat cardiac function depending on antioxidant ability. ( Huang, H; Pan, XH; Qian, LB; Shan, J; Wang, HP; Xia, Q, 2007) |
| "Treatment with carvedilol for 5 weeks prevented the inhibition of endothelium-dependent relaxation and the decrease of serum NO levels caused by diabetes." | 1.34 | Carvedilol ameliorates endothelial dysfunction in streptozotocin-induced diabetic rats. ( Chen, F; Fu, GS; Huang, H; Ke, XY; Qian, LB; Wang, HP; Xia, Q, 2007) |
| "Carvedilol treatment increased activities of antioxidant enzymes and expression of Bcl-2 in healthy rats as well as diabetic rats." | 1.33 | Carvedilol protected diabetic rat hearts via reducing oxidative stress. ( Huang, H; Pan, XH; Qian, LB; Shan, J; Wang, HP, 2006) |
| "Carvedilol treatment did not significantly alter nerve conduction in non-diabetic rats." | 1.29 | Neuroprotective effects of carvedilol in diabetic rats: prevention of defective peripheral nerve perfusion and conduction velocity. ( Cameron, NE; Cotter, MA, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Farhat, R | 1 |
| de Santana-Van Vliet, E | 1 |
| Su, G | 1 |
| Neely, L | 1 |
| Benally, T | 1 |
| Chan, O | 1 |
| Morsy, MA | 1 |
| Ibrahim, SA | 1 |
| Amin, EF | 1 |
| Kamel, MY | 1 |
| Abdelwahab, SA | 1 |
| Hassan, MK | 1 |
| Zhang, R | 1 |
| Kang, X | 1 |
| Wang, Y | 1 |
| Wang, F | 1 |
| Yu, P | 1 |
| Shen, J | 1 |
| Fu, L | 1 |
| Diogo, CV | 1 |
| Deus, CM | 1 |
| Lebiedzinska-Arciszewska, M | 1 |
| Wojtala, A | 1 |
| Wieckowski, MR | 1 |
| Oliveira, PJ | 1 |
| Huang, H | 3 |
| Shan, J | 2 |
| Pan, XH | 2 |
| Wang, HP | 3 |
| Qian, LB | 3 |
| Xia, Q | 2 |
| Fu, GS | 1 |
| Chen, F | 1 |
| Ke, XY | 1 |
| Cotter, MA | 1 |
| Cameron, NE | 1 |
| Bartosíková, L | 1 |
| Necas, J | 1 |
| Pavlícek, V | 1 |
| Kuchticková, S | 1 |
| Frána, P | 1 |
| Zavadilová, R | 1 |
| Husek, K | 1 |
9 other studies available for carvedilol and Alloxan Diabetes
| Article | Year |
|---|---|
Carvedilol prevents impairment of the counterregulatory response in recurrently hypoglycaemic diabetic rats.
Topics: Adrenergic beta-Antagonists; Animals; Awareness; Carvedilol; Deoxyglucose; Diabetes Mellitus, Experi | 2021 |
Carvedilol ameliorates early diabetic nephropathy in streptozotocin-induced diabetic rats.
Topics: Animals; Antioxidants; Carbazoles; Carvedilol; Creatinine; Diabetes Mellitus, Experimental; Diabetic | 2014 |
Effects of carvedilol on ventricular remodeling and the expression of β3-adrenergic receptor in a diabetic rat model subjected myocardial infarction.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Diabetes Mellitus, Experimental; Diabe | 2016 |
Carvedilol and antioxidant proteins in a type I diabetes animal model.
Topics: Adrenergic beta-Antagonists; Animals; Antioxidants; Blood Glucose; Carbazoles; Carvedilol; Caspase 3 | 2017 |
Carvedilol improved diabetic rat cardiac function depending on antioxidant ability.
Topics: Animals; Antihypertensive Agents; Antioxidants; Blood Glucose; Blood Pressure; Carbazoles; Carvedilo | 2007 |
Carvedilol protected diabetic rat hearts via reducing oxidative stress.
Topics: Animals; Antioxidants; Blood Glucose; Body Weight; Carbazoles; Carvedilol; Diabetes Mellitus, Experi | 2006 |
Carvedilol ameliorates endothelial dysfunction in streptozotocin-induced diabetic rats.
Topics: Adrenergic beta-Antagonists; Animals; Aorta, Thoracic; Blood Glucose; Blood Pressure; Blotting, West | 2007 |
Neuroprotective effects of carvedilol in diabetic rats: prevention of defective peripheral nerve perfusion and conduction velocity.
Topics: Animals; Carbazoles; Carvedilol; Diabetes Mellitus, Experimental; Male; Neural Conduction; Periphera | 1995 |
[Effects of carvedilol, a sympatholytic, in experimental alloxan diabetes in laboratory rats].
Topics: Adrenergic Antagonists; Animals; Blood Glucose; Carbazoles; Carvedilol; Diabetes Mellitus, Experimen | 1998 |